<DOC>
	<DOCNO>NCT01006031</DOCNO>
	<brief_summary>Objective : To evaluate efficacy safety high dose peginterferon-alfa 2a ( 360 ug per week ) plus ribavirin ( 800 mg b.i.d . ) HIV-infected patient compensate liver cirrhosis HCV genotype 1 4 without previous virological response ( * ) standard dose treatment drug . ( * ) Non previous virological response : decrease plasma RNA-HCV least 2 log10 12 week treatment breakthrough viremia treatment . Additionally , study evaluate influence simultaneous peginterferon-alfa 2a ribavirin plasma concentration early viral response ( EVR ) sustain viral response ( SVR ) patient . Method : Pilot clinical trial , phase II-III , open label multicenter patient several hospital Servicio Andaluz de Salud enrol . The usual clinical analytical follow perform additional blood sample obtain determination interferon ribavirin plasma level . The primary end point sustain virologic response ( define undetectable serum HCV-RNA 24 week cessation treatment ) . Likewise , rapid virological response ( 4 week treatment ) , early virological response ( 12 week ) , end treatment response rate evaluate well relationship plasma interferon ribavirin concentration determine ELISA HPLC , respectively . The safety tolerability study medication evaluate mean clinical adverse event , physical examination laboratory result . The evolution liver fibrosis evaluate compare basal end treatment result transient elastometry .</brief_summary>
	<brief_title>Retreatment With High Doses pegIFN Alfa-2a Ribavirin Previous Nonresponders HIV-coinfected Patients With Cirrhosis Due HCV 1-4</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Age old 18 year HIVinfected patient compensate liver cirrhosis HCV genotype 1 4 without previous virological response ( * ) standard dose treatment drug . Women childbearing age : negative pregnancy test Ability understand sign write consent form HCV genotypes different 1 4 Acute chronic hepatitis B infection ( positivity hepatitis B surface antigen plasma DNA ) concomitant cause liver disease Pregnancy breast feeding . Decompensated liver disease baseline . Neutropenia &lt; 1000/uL , anemia &lt; 100 g/L thrombocytopenia &lt; 20.000/uL . Creatinine clearance &lt; 50 mL/min . Concomitant treatment immunomodulators zidovudine , didanosine stavudine . Organ bone marrow transplantation Current alcoholism iv drug abuse . Methadone allow . Current neoplasm and/or antitumor chemotherapy immunomodulators Psychosis uncontrolled clinical depression Autoimmune disease , include autoimmune hepatitis History significant cardiovascular disease ( NYHA IIIIV ) include limit uncontrolled hypertension , angina pectoris , myocardial infarction , coronary artery surgery congestive heart failure . Thyroid dysfunction . Clinically significant retinal abnormality Inability understand sign write consent form</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Liver cirrhosis</keyword>
	<keyword>Hepatitis C virus</keyword>
	<keyword>HIV infection</keyword>
	<keyword>Pegylated interferon alfa-2a</keyword>
	<keyword>Ribavirin</keyword>
	<keyword>Treatment experience</keyword>
</DOC>